Vifor Pharma begins new tests of Ferinject in patients with heart failure, iron deficiency
Vifor Pharma recently said it began three new tests for Ferinject (ferric carboxymaltose), its intravenous iron replacement therapy for patients with systolic heart failure and iron deficiency.
In the AFFIRM-AHF, FAIR-HF2 and HEART-FID tests, scientists are measuring how well Ferinject would work in helping people fighting heart failure and too little iron to get better.
The AFFIRM-AHF test will measure how well Ferinject works in people who had gone through acute heart failure, a Vifor release said. For this test, 1,100 people will be getting either Ferinject or a placebo after they leave the hospital after after heart failure. The study will assess how many have to go back to the hospital and how many people die.
The FAIR-HF2 test, which the University Medical Center Hamburg-Eppendorf will pay for, will involve 1,200 people with chronic heart failure and too little iron. The study assess how many have to go back into the hospital for the same issue and how many die.
The HEART-FID test, which American Regent will do, will measure how well Ferinject works compared to the placebo in affecting how many people die after a year, how many people go back to the hospital for heart failure of increasing in severity, and what the results of six-minute walk look like after six months for people who have heart failure and too little iron.
These three tests came after tests that showed Ferinject worked better than a placebo or the current leading medicine.
Organizations in this story
Vifor Pharma Flughofstrasse 61 P.O. Box CH-8152 Glattbrugg